{
    "title": "Astrazeneca paying up to \u00a34.7bn for global rights to potential treatment for breast and lung cancer",
    "url": "https://www.dailymail.co.uk/money/markets/article-8565301/Astrazeneca-4-7bn-deal-cancer-drug.html",
    "date": "2020-07-27",
    "keywords": [
        "cancer",
        "treatment",
        "daiichi",
        "ds1062",
        "drug",
        "share",
        "fund",
        "astrazeneca",
        "breast",
        "lung",
        "sankyo",
        "boss",
        "astra",
        "enhertu",
        "year",
        "collaboration",
        "oncology",
        "investment",
        "account",
        "fee",
        "giant",
        "vaccine",
        "covid19",
        "hand",
        "type",
        "chemotherapy",
        "medicine",
        "success",
        "protein",
        "side",
        "approval",
        "soriot",
        "status",
        "launch",
        "pipeline",
        "leadership",
        "record",
        "brummer",
        "health",
        "england",
        "duo",
        "synairgen",
        "article",
        "world",
        "ability",
        "japan",
        "part",
        "class",
        "adcs",
        "pair",
        "announcement",
        "reception",
        "cent",
        "research",
        "jose",
        "baselga",
        "phase",
        "trial",
        "role",
        "firm",
        "diy",
        "capital",
        "risk",
        "isa",
        "trade",
        "month",
        "community",
        "model",
        "affiliate",
        "product",
        "money",
        "commission",
        "editorial",
        "independence",
        "investing",
        "platform"
    ],
    "category": [
        "money",
        "markets"
    ]
}